Filter Results:
(617)
Show Results For
- All HBS Web
(617)
- People (4)
- News (113)
- Research (425)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(617)
- People (4)
- News (113)
- Research (425)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
you can make money in many creative industries by selling specialized products to niche markets identified via the Internet. For example, the new CEO of GlaxoSmithKline, the pharmaceuticals giant, likens the search for blockbusters to... View Details
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.
John T. Gourville
John Gourville is the Albert J. Weatherhead, Jr. Professor of Business Administration at the Harvard Business School. He joined the HBS Marketing Unit in 1995 after receiving his Ph.D. at the University of Chicago in marketing and behavioral research. His most... View Details
- May 2023
- Case
Legacy Partners
By: Royce Yudkoff and Richard S. Ruback
Stephen Holbrook and Austin Pulsipher (both HBS '19) had been leading Nutrishare since acquiring the company six months earlier in mid-2021. The company, based in Sacramento CA, was a compounding pharmacy serving Total Parenteral Nutrition ("TPN") patients nationwide.... View Details
Keywords: Acquisition; Growth and Development Strategy; Competitive Strategy; Business or Company Management; Pharmaceutical Industry
Yudkoff, Royce, and Richard S. Ruback. "Legacy Partners." Harvard Business School Case 223-092, May 2023.
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
is Ciba Vision. Established in the early 1980s as a unit of the Swiss pharmaceutical giant Ciba-Geigy (now Novartis), the Atlanta-based Ciba Vision sells contact lenses and related eye-care products to optometrists and consumers. Although... View Details
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
scientific-driven process. So corporations made enormous investments to create ivory towers where scientists would think great thoughts. At first it seemed very appealing, but as the fifties moved into the sixties and the sixties moved into the seventies, disillusion... View Details
Keywords: by Carmen Nobel
- March 2023
- Case
Roche: ESG and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details
Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: ESG and Access to Healthcare." Harvard Business School Case 123-075, March 2023.
- 11 Aug 2003
- Research & Ideas
Cheap, Fast, and In Control: How Tech Aids Innovation
experimentation and are triggering fundamental changes in R&D processes and performance in such fields as integrated circuit design, automotive development, and pharmaceutical drug discovery. Computer modeling and simulation, rapid... View Details
Keywords: by Wendy Guild
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Pharmaceutical Industry; Pharmaceutical Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- February 2002
- Case
Fighting AIDS and Pricing Drugs
In early 2001, makers of AIDS drugs were suing to prevent developing countries from violating their patents. The issue was driven by price. The developing countries could not afford the market price for these drugs. At the same time, the drug companies were reluctant... View Details
Keywords: Developing Countries and Economies; Patents; Price; Strategy; Globalized Markets and Industries; Pharmaceutical Industry
Gourville, John T. "Fighting AIDS and Pricing Drugs." Harvard Business School Case 502-061, February 2002.
- September 2005 (Revised June 2006)
- Case
WuXi PharmaTech
By: Richard G. Hamermesh and Simin Zhou
WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details
Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China
Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)
- Web
All Industries
Entertainment / Media 3% $150k 25th Percentile Base $165k Median $184k 75th Percentile Base $13k 40% Receiving $21k 60% Receiving Health Care 6% + – Expand Row $145k 25th Percentile Base $165k Median $185k 75th Percentile Base $30k 66% Receiving $29k 71% Receiving... View Details
- 09 Feb 2024
- HBS Case
Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive
surgery or drugs it is not going to be widely taken up. Americans are very overworked. People are terribly stressed. How do they find the time for a diet like that? Editor's note: Regina Herzlinger doesn't have a financial stake in any of the View Details
- January 2017
- Case
Medtronic: Making the Big Leap Forward (A)
By: William W. George and Monica Baraldi
In 2014, Medtronic was about to execute a $50 billion acquisition of Ireland-based Covidien. Medtronic CEO Omar Ishrak was committed to building the largest medical technology company in the world while broadening its ability to fulfill its mission of “alleviating... View Details
Keywords: Acquisition; Medtronic; Covidien; Mission; Tax Inversion; Business Strategy; Leadership; Mergers and Acquisitions; Pharmaceutical Industry; Republic of Ireland; Europe; Minnesota; United States
George, William W., and Monica Baraldi. "Medtronic: Making the Big Leap Forward (A)." Harvard Business School Case 317-031, January 2017.
- 15 Jan 2019
- First Look
New Research and Ideas, January 15, 2019
faster-growing companies to raise more capital. These results highlight the importance of institutions in enabling the provision of entrepreneurial capital to young companies. In Search of Organizational Alignment Using a 360-Degree... View Details
Keywords: Dina Gerdeman
William E. Fruhan
Professor WILLIAM E. FRUHAN, JR. is George E. Bates Professor, Emeritus at the Harvard Business School. He received his BS degree from Yale University, and his MBA and DBA degrees from Harvard University. He has served as Senior Associate Dean and Director of... View Details
- February 2003 (Revised August 2005)
- Case
UCB (A): Managing Information for Globalization and Innovation
By: F. Warren McFarlan and Brian DeLacey
This case presents a complex total MIS strategy case for a $3 billion European pharmaceutical/chemicals company based in Brussels. It covers corporate strategy alignment of IT portfolio, IT operations issues, and global coordination of IT. View Details
Keywords: Information Technology; Operations; System; Corporate Strategy; Investment Portfolio; Globalization; Pharmaceutical Industry; Pharmaceutical Industry; Brussels
McFarlan, F. Warren, and Brian DeLacey. "UCB (A): Managing Information for Globalization and Innovation." Harvard Business School Case 303-091, February 2003. (Revised August 2005.)
- Web
Employment Data Trends
Employment Data Trends Employment Data Trends Trends Career Data Internship Data Trends by Industry 2020 2021 2022 2023 2024 Consulting 24% 23% 26% 25% 18% Consumer Products 3% 3% 3% 4% 3% Entertainment / Media 2% 3% 3% 1% 3% Health Care 7% 6% 5% 5% 6% Biomed / View Details
- 25 Oct 2004
- Research & Ideas
Planning for Surprises
just two suppliers, while Great Britain has five suppliers to reduce the risk of supply disruptions. While fear of lawsuits has played a role, the fundamental problem is that the economics of vaccine production are unattractive for View Details
Keywords: by Martha Lagace